{"id":"norepinephrine-versus-midodrine-octreotide","safety":{"commonSideEffects":[{"rate":null,"effect":"Hypertension"},{"rate":null,"effect":"Tachycardia"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Abdominal pain"},{"rate":null,"effect":"Hyperglycemia"},{"rate":null,"effect":"Peripheral ischemia"}]},"_chembl":{"chemblId":"CHEMBL1201212","moleculeType":"Small molecule","molecularWeight":"254.29"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Norepinephrine is a catecholamine that stimulates alpha and beta-adrenergic receptors to increase systemic vascular resistance and blood pressure. Midodrine is an alpha-1 adrenergic agonist that increases peripheral vasoconstriction, while octreotide is a somatostatin analog that reduces splanchnic blood flow and portal pressure. This combination is used in acute variceal hemorrhage management to maintain hemodynamic stability and reduce rebleeding risk.","oneSentence":"Norepinephrine acts as a sympathomimetic to increase blood pressure, while midodrine and octreotide are used as alternative or adjunctive agents to manage variceal bleeding and portal hypertension complications.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-27T23:57:37.426Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Acute variceal hemorrhage in portal hypertension"},{"name":"Prevention of variceal rebleeding in cirrhotic patients"}]},"trialDetails":[{"nctId":"NCT03455322","phase":"PHASE4","title":"Norepinephrine Infusion Versus Midodrine & Octreotide in Patients With Hepatorenal Syndrome Type 1.","status":"COMPLETED","sponsor":"National Hepatology & Tropical Medicine Research Institute","startDate":"2018-08-15","conditions":"Renal Impairment in Hepatorenal Syndrome","enrollment":60},{"nctId":"NCT04522297","phase":"NA","title":"Nor-epinephrine Versus Midodrine/Octreotide in Patients With Hepatorenal Syndrome","status":"COMPLETED","sponsor":"National Hepatology & Tropical Medicine Research Institute","startDate":"2018-04-15","conditions":"Hepato-Renal Syndrome","enrollment":91}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":7,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"norepinephrine versus midodrine & octreotide","genericName":"norepinephrine versus midodrine & octreotide","companyName":"National Hepatology & Tropical Medicine Research Institute","companyId":"national-hepatology-tropical-medicine-research-institute","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Norepinephrine acts as a sympathomimetic to increase blood pressure, while midodrine and octreotide are used as alternative or adjunctive agents to manage variceal bleeding and portal hypertension complications. Used for Acute variceal hemorrhage in portal hypertension, Prevention of variceal rebleeding in cirrhotic patients.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}